This Pharma Stock is in focus after reporting its Q4 FY25 results, where it reported robust performance on the Net Profit front with an increase of 830 percent on a QoQ basis and a turnaround from loss to profit on a YoY basis. Stock jumped by 15.88 percent.
With a market capitalisation of Rs. 3,898 Crore, the stock of Dishman Carbogen Amcis opened at Rs. 229, up 4.09 percent from yesterday’s close, and after opening, it made a high of Rs. 254.95, up 15.88 percent. Additionally, the Yearly return for the stock is 29 percent, and the past 5-year return is an impressive 237 percent.
Financial Highlights
The company reported a 9.41 percent YoY increase in revenue from Rs. 654.71 Crore in Q4FY24 to Rs. 716.34 Crore in Q4FY25. On a QoQ basis, the company reported an increase of 4.98 percent in revenue from Rs. 682.34 Crore in the previous quarter.
On a YoY Basis, the company saw a turnaround from a loss of Rs. 69.92 Crores in Q4FY24 to a profit of Rs. 43.09 Crores in Q4FY25. On a QoQ basis company reported a Net Profit increase of 830.66 percent from 4.63 Crore in Q3FY25
The turnaround from loss to Profit on a YoY basis can be attributed to Expenses exceeding the revenue from operations in Q4FY24, with the cost of materials consumed being high compared to revenue. On a QoQ basis, the increase in Net Profit can be attributed to tax credits that the company received in Q4FY25.
Also read: Stock under ₹50 hits 10% upper circuit after reporting 123% QoQ increase in net profit
About the Company
Established in 1983 by Janmejay R. Vyas & Headquartered in Ahmedabad, Dishman Carbogen Amcis Limited (DCAL) is a global pharmaceutical company specialising in contract research and manufacturing services (CRAMS) for the pharmaceutical, biotechnology, and healthcare industries.
The company has evolved into a significant player in the development and production of active pharmaceutical ingredients (APIs), highly potent APIs, and complex chemical compounds.
Written By Abhishek Das
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
